GPhA CEO to hold Conference Call on Drug Costs, Increasing Generic Competition
WASHINGTON, Sept. 16, 2016 /PRNewswire-USNewswire/ -- Chip Davis, President and CEO, Generic Pharmaceutical Association (GPhA) will hold a news conference Monday to outline his organization's response to the latest debate over the lack of competition in the prescription drug market.
"The current debate about drug pricing is getting a lot of attention for particular price fluctuations of certain drugs, but we shouldn't let it distract us from taking a comprehensive approach to making medicine more affordable and accessible to the American people," Davis said.
GPhA has outlined a 5-point plan with specific policy proposals for increasing competition and for speeding medicines to patients.
Davis will also address the current state of play for these proposals and discuss the political environment around a number of proposals that would actually serve to chill competition.
"Given the sensitivities, it's puzzling that some stakeholders in this debate are moving to stifle policies that would actually serve to increase access to affordable medicines," Davis added.
RSVP: Steve Arnoff 202.249.7113 firstname.lastname@example.org
Monday, September 19th, 2016
11:00 am EST
Dial In: 1-800-351-4890
Visit www.RxSolutions.us for more information on the GPhA Policy Prescriptions to increase generic competition.
GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals fill 88 percent of the prescriptions dispensed in the U.S. but consume just 28 percent of the total drug spending. Additional information is available at gphaonline.org. Follow us on twitter: @gpha.
Contact: Steve Arnoff 202.249.7113
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/gpha-ceo-to-hold-conference-call-on-drug-costs-increasing-generic-competition-300329506.html
SOURCE Generic Pharmaceutical Association